Semax: FDA's Own Reviewers Said No, and the Committee Voted Yes Anyway
The agency excluded the entire Russian clinical literature on a translation rule, then judged effectiveness on two references. One was submitted by the nominator and concluded against the use it was submitted for.
What it is
Semax is a peptide, a chain of seven amino acids linked end to end, and in Russia it is an ordinary prescription medicine, sold as nasal drops. In the United States it is approved for nothing.
On 11 May 2026, FDA's reviewers proposed not adding Semax to the list of bulk substances compounding pharmacies may lawfully use. On 24 July 2026, the advisory committee reading that document voted 8 to 5, one abstention, to add it anyway.
Not approval. The indications on the table were cerebral ischemia, meaning a stroke caused by the blood supply being cut off, plus migraine and trigeminal neuralgia, a facial nerve pain. The tally comes from news coverage, because FDA has posted no minutes. The vote is not binding and changes nothing about Semax's unapproved status.
What the trials found
FDA named the Russian stroke literature and then excluded all of it for want of verified English translations, citing 21 CFR 10.20(c)(2). The excluded papers were Miasoedova 1999, Gusev 1997, Gusev 2005 and Gusev 2018, which is essentially the entire human efficacy base. What was left for cerebral ischemia was one conference abstract with no full paper behind it.
The other surviving reference came from the nominators themselves. Koroleva 1996 gave a single 0.5 mg/kg intranasal dose to 37 adults, unblinded and uncontrolled, split across migraine, trigeminal neuralgia and dental plexalgia. No change in the neuralgia group. In the migraine arm 4 of 12 reported the headache stopping 90 to 120 minutes later. FDA noted no baseline characterisation, no blinding, no control, no standard deviations. The paper's own conclusion is that semax does not exhibit analgesic activity by itself.
The exclusion was procedural, and nothing in the FDA document evaluates what is in those papers. The meta-analysis is the most honest document in the file. Shmonin and colleagues found 8 nominally suitable studies covering 654 patients, could pool only 3 because the rest did not share endpoints, reported benefits on three stroke scales, and then recommended that a proper trial still be run. That was 2018, after two decades of Russian clinical use.
What the mechanism rests on
The story about BDNF, a protein that helps nerve cells survive and connect, is real, small and Russian. In rat hippocampus, after a single 50 mcg/kg dose, BDNF protein went up 1.4 fold and its messenger RNA up 3 fold. (PMID 16996037) Notice the split. Protein moved by less than half, transcript by three times, and that distinction disappears in marketing copy, hardest around the number everybody quotes: an eight fold rise in BDNF messenger RNA, measured in rat glial cell cultures. (PMID 11457573) A reading from cells in a dish, sold as a protein effect in an animal.
How it compares
Semax, Selank and Epithalon all come out of Russian research institutes, and buyers read that shared origin as a shared evidence base.
| Approved? | Human trials behind it | What that evidence covers | |
|---|---|---|---|
| Semax | A prescription medicine in Russia, unapproved in the United States | Eight human references in FDA's search, two left standing | Stroke, migraine and facial nerve pain, every study of it up the nose |
| Selank | Registered in Russia in 2009, nowhere else | Three, all Russian, all measured against a sedative, none reporting a dose | Anxiety scores in 192 patients, given as nasal drops |
| Epithalon | No approved product in any market FDA checked | Three, one of them randomised, none by injection under the skin | A melatonin breakdown product in 20 women on night shifts, and an eye result with no patient count |
None of the three was tested by the route it is sold in, and none of the three records carries to the other two.
Where the dose came from
Every approved Semax product in the world is nasal drops. Peptogen makes two in Russia, 0.1 percent at 50 mcg a drop and 1 percent at 500 mcg a drop, and there is no approved injectable anywhere.
- 1Community convention · 500 to 3,000 mcg per day, intranasalRoughly 250 to 1000 mcg a time, one to three times daily.
- 2Russian 0.1 percent label · 800 to 8,000 mcg per day, intranasalSingle dose 200 to 2000 mcg, four times daily, 10 to 14 days.
- 3Russian 1 percent label, moderate stroke · 6,000 to 12,000 mcg per day, intranasal2 to 3 drops per nostril, 3 to 4 times daily, 10 days.
- 4Russian 1 percent label, severe stroke · 12,000 to 20,000 mcg per day, intranasal3 to 4 drops per nostril, 4 to 5 times daily. Highest labelled dose anywhere.
What circulates sits at the low end of what the Russian label already allows, though it is still vendor consensus, not a regimen any trial produced.
What could go wrong
FDA's finding on route is flat: it could find no literature on subcutaneous administration, meaning injection under the skin, and the only route discussed anywhere was intranasal. The American market runs on the other one, on 2.5 mg/mL injectables and 30 mg vials sold "for research purposes only." Injected Semax has zero published human literature. No efficacy, no safety, nothing on how long a dose lasts.
The second hazard is arithmetic. Semax is MEHFPGP, average molecular weight 813.9. N-Acetyl Semax is the same thing acetylated at the head, 856.0, because the acetyl group adds 42.04 daltons and nothing else. N-Acetyl Semax Amidate is acetylated at the head and amidated at the tail, 855.0, because amidation swaps an oxygen for an NH and takes off 0.984 daltons.
So the two acetylated forms sit about one dalton apart, and the parent sits 42 daltons below both. Mass spectrometry settles only half of that. It tells you instantly that you are not holding plain Semax, because 42 daltons is enormous. It cannot tell you which of the two acetylated forms you have, because a certificate reporting nominal mass will not resolve one dalton. How to read a certificate of analysis covers the rest.
The naming is worse than the chemistry. Vendors and at least one chemical database hang the same CAS number on products labelled "N-Acetyl Semax" and on products labelled "N-Acetyl Semax Amidate," and FDA hit the same kind of failure inside the nomination packages themselves, which carried certificates titled "Semax Acetate" that identified the free base.
Almost nothing is published on the derivatives either. I found no indexed study of the amidate in any species. The one study treating acetylation as a distinct compound found it abolished a protective effect the parent had, attributed to losing the free amine at the head. (PMID 27586814) The opposite direction from the marketing.
What nobody knows
Whether the four excluded papers change the answer. They are still untranslated, and a verified translation is all it would take to find out.
Whether it holds up anywhere else. Outside Russia I found no clinical replication at all.
What it does in a brain. I found no measurement of brain BDNF in a human being, and FDA's own read was that the mechanism is not established.
Whether any schedule matters. Cycling is pure convention, no study has compared any schedule, and the longest adult course FDA found was 10 days.
My take
The evidence being weak is not the thing to carry out of this. The record was emptied by a rule, and then a vote was taken on what was left.
FDA's reviewers did their job correctly, because an agency cannot evaluate papers it cannot verify, and the result is still a formal federal assessment of a drug that never touched the four studies holding nearly all its human data. A committee read that assessment, disagreed, and voted it onto the list anyway. Both moves are defensible. Neither produces knowledge. Nobody translated the papers, nobody ran the trial the Russian meta-analysts asked for in 2018, and I could find nobody who has published a word about the route Americans actually use.
If you have bought Semax in the past year, I want to know which of the three names was on the vial, and whether the certificate named the same molecule as the CAS number printed next to it.
Frequently asked
Is Semax FDA approved?
No. Semax is unapproved for anything in the United States. On 11 May FDA's reviewers proposed not adding Semax to the 503A Bulks List, which is the set of raw substances a compounding pharmacy may lawfully work with, and on 24 July an advisory committee voted 8 to 5, with one abstention, to add it anyway. That vote is not binding and it changes nothing about the unapproved status.
Is there any real evidence that Semax works?
The record FDA was able to use came down to two references, and the agency judged both inadequate. What was left for cerebral ischemia was one conference abstract with no full paper behind it, plus a 1996 study that gave a single intranasal dose to 37 adults with no blinding and no control group, submitted by the people asking for the listing, whose own conclusion was that semax does not relieve pain by itself. Separately, a 2018 Russian meta-analysis pooled 3 of 8 studies covering 654 patients, reported benefits on three stroke scales, and then said a proper trial still needed to be run. Outside Russia I found no clinical replication.
What is the difference between Semax, N-Acetyl Semax and N-Acetyl Semax Amidate?
Semax is the parent peptide, MEHFPGP, average molecular weight 813.9. N-Acetyl Semax is the same peptide acetylated at the head, 856.0. N-Acetyl Semax Amidate is acetylated at the head and amidated at the tail, 855.0. So the two acetylated forms sit about one dalton apart while the parent sits 42 daltons below both, which means a certificate reporting nominal mass can show that a product is not plain Semax but cannot tell you which of the two acetylated forms it is.
Has anyone studied injected Semax?
Not in the published human record. Every approved Semax product in the world is nasal drops, every study in FDA's review used the intranasal route, and FDA reported that it could find no literature on subcutaneous administration. Most of what is sold in the United States is the other thing, injectable solutions and vials sold for research purposes only, and for that route I could find no published human efficacy, safety or pharmacokinetic data.
Where does the usual Semax dose come from?
Not from a trial. The published figures are the labels of the two registered Russian nasal products, a 0.1 percent drop at 50 mcg a drop and a 1 percent drop at 500 mcg a drop, and the 1 percent label for severe stroke is the highest labelled amount anywhere. What circulates sits at the low end of what that Russian label already allows, and it is vendor consensus rather than a regimen any trial produced. Cycling is pure convention, no study has compared any schedule, and the longest adult course FDA found was 10 days.
Is Semax banned by WADA?
It does not appear on the 2026 WADA Prohibited List. I pulled all 26 pages and the word is not there. The common claim that the S0 catch-all covers it does not survive reading S0, which covers substances with no current approval by any health authority, and Semax holds a current Russian one.
This content is for educational and informational purposes only and is not medical advice. Peptides discussed are research compounds and may not be approved for human use. Nothing here should be used to diagnose, treat, cure, or prevent any disease. Always consult a qualified healthcare professional before starting any peptide, supplement, or protocol. Individual responses vary. Do not self-administer compounds without proper medical supervision.
Get the next one in your inbox
Free. One email a week at most. Unsubscribe in one click.
Double opt-in · No spam · Unsubscribe anytime
Comments
More in Cognitive and neuro
- P-21 Is Not a Cerebrolysin Derivative, and Every Study I Found Is RodentEvery number I could find attached to this compound came out of a mouse or a rat, fed in chow, put down a tube into the stomach, leaked from a pellet under the skin, or injected into the abdomen. I found no study, in any species, of the injection under the skin people buy.
- PE-22-28: The Antidepressant Claim Is Ten Mice in a Water CylinderOne laboratory in every paper I found, male mice only, injected into the abdominal cavity. The 23 hour duration figure was measured on a different molecule, and the same group later reported the effect reverses direction with dose.
- Cerebrolysin Is a Licensed Medicine Made of Pig Brain, and Its Own Label Says Nobody Can Measure ItAustria has prescribed it since 1996 with a dosing table by condition. Ten cerebrolysin papers are flagged retracted on PubMed, and the amount people inject at home stops exactly where the label's syringe limits stop, 5 mL into a muscle and 10 mL into a vein.